ATAI is an internationally active biotech company investing in and acquiring therapeutics focusing on longevity and mental wellbeing.
Atai Life Sciences has raised €273M across 3 funding rounds from 4 investors, most recently a Series D+ round in Mar 2021. Based in Munich, Germany; founded 2018; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2021-03-03 | Series D+ | €131M | Apeiron Investment Group,Thiel Capital,Woodline Partners | View deal → |
| 2020-11-23 | Series C | €105M | — | View deal → |
| 2019-01-01 | Series B | €38M | Subversive Capital | View deal → |
